Clinical Development, Immune Response, In-Vitro and In-Vivo

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Development

Immune Response

In-Vitro

In-Vivo

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6.

Antibody

Antibody In-Vivo Vaccination Vaccine

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research

Research In-Vitro In-Vivo Development

Clinical Research Informer

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The evolution of assays for immuno-oncology research

Stay Connected